🔗 Share this article

As the United States proceeds with historic revisions to its vaccine schedules, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations throughout the pandemic and has concentrated on alleged fatalities following COVID-19 vaccination in her brief position at the FDA.

Proposed Overhauls to Childhood Immunization Schedule

Health officials planned to reveal radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of alignment with much of the global community with insufficient data for public health gain. The announcement has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing some pediatric immunization guidelines in the US to become more in line with the Danish model, a country with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious experience in medication creation, regulation or management, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “understand laws and regulations and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who led the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one have to be supervised,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial administrative element to the position, which supervises more than 5,000 personnel. “It is a huge leadership role, if you do it right,” Woodcock said.

Official Statement and Disputed Programs

When asked about inquiries about Dr. Høeg's credentials and whether this assignment represents more teamwork among FDA leaders on vaccines, a representative said that the “questions stem from inaccurate assumptions”.

“Her experience aligns with the duties of her position,” the official said, citing the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial rapid therapy clearance system that allegedly troubled her preceding directors. “How are these medications being chosen for this expedited pathway? Who makes the calls?” Dr. Howard said. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, except for shots.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, history, some experts said. She released a analysis using non-validated public submissions to determine the rate of myocarditis following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership featured altering guidelines for recently developed shots and halting “unnecessary” vaccines, she remarked after the election on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccinations.

“She is an thorough true believer who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a very deceptive, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|